Determine the Efficacy and Side Effects of Tenofovir Alafinamide and Tenofovir Disoproxil Fumarate in Patients with Hepatitis B Infection

Abstract

Objective: To determine the efficacy and side effects of tenofovir alafenamide (TAF) and tenofovir disoproxil
fumarate (TDF) in patients with Hepatitis B infection.
Material and Methods: The study design was Observational study using Non-Probability Purposive Sampling.
The study was conducted in the Hepatitis Clinic, Jinnah Hospital, Lahore. The duration was February 01, 2020 –
March 09, 2024A total of 114 patients were enrolled and monitored for 144 weeks. Patients were randomized
into two groups using a double-blind methodology: A total of 57 patients were assigned to receive TDF
(Group A), and an equal number received TAF (Group B). Demographic details, treatment efficacy (defined
as HBV DNA < 29 IU/ml), and safety outcomes were recorded.
A total of 114 patients were randomized into two groups: 57 received TDF (Group A) and 57 received TAF
(Group B). Patients were monitored for 144 weeks. Outcomes were analyzed using SPSS version 24.0, with
t-tests and Chi-square tests (p < 0.05)
Results: The mean age was 49.32 ± 22.87 years in Group A and 48.14 ± 23.02 years in Group B (P = 0.89).
Treatment efficacy was achieved in 38 (66.7%) cases in Group A and 32 (56.1%) in Group B (P = 0.33). At
144 weeks, 78.1% of Hepatitis B e antigen (HBeAg)-positive and 88.2% of HBeAg-negative patients in
Group A had HBV DNA < 29 IU/ml, compared to 82.75% and 92.8% in Group B. Group B showed a significantly
lower decline in estimated glomerular filtration rate (eGFR) (≥ 25% at week 144) compared to Group A
(8.77% vs. 24.56%; P = 0.042).
Conclusion: TAF demonstrated comparable efficacy to TDF with improved renal and bone safety over 144
weeks.
Keywords: Hepatitis B, Tenofovir alafinamide, Tenofovir disoproxil